Thrombocytopenia sirolimus

The most common adverse events reported with sirolimus are leukopenia (20%), thrombocytopenia (13% to 30%), and hyperlipidemia (38% to 57%).11,31 Other adverse effects include delayed wound healing, anemia, diarrhea, arthralgias, rash, and mouth ulcers. Sirolimus has an FDA black-box warning in newly transplanted liver and lung recipients.11 In liver transplant recipients, use of sirolimus immediately after transplant is associated with an increased risk of hepatic artery thrombosis, graft loss, and death. In lung transplant... 

Sirolimus is a potent immunosuppressive agent. To prevent thrombocytopenia and hypercholesterolemia, optimize efficacy, and reduce organ rejection, assays were developed to monitor concentrations of sirolimus in the whole blood of patients under treatment.40"12 Wallemacq et al.43 developed and validated a simple high-throughput HPLC-MS/MS method to routinely monitor sirolimus... 

Rapamycin, also known as sirolimus, is a new macrolide antibiotic that interacts with cellcycle regulating proteins and inhibits cell division. The main side effects are thrombocytopenia and hyperlipidaemia. There is also evidence that it causes interstitial pneumonitis, which may resolve on withdrawing the drug or dose reduction. The drug is currently being assessed for combination therapy with tacrolimus or cyclosporin. 

Hong JC, Kahan BD. 2000. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients Risk factors, incidence, progression and management. Transplantation. 69 2085-2090. 

Adverse Effects. Sirolimus may cause blood lipid disorders, including hypercholesterolemia and hypertriglyceridemia.42 Other side effects include blood disorders (anemia, leukopenia, thrombocytopenia),... 

Toxicities of sirolimus can include profound myelosuppression (especially thrombocytopenia), hepatotoxicity, diarrhea, hypertriglyceridemia, and headache. 

Thrombocytopenia, probably related to sirolimus, as well as significant reversible reductions in platelet and white blood cell counts have been found (SEDA-20, 346). 

Sirolimus exerts its activity by inhibiting T-cell response to IL-2. The adverse effects associated with sirolimus include thrombocytopenia, anemia, and hyperlipidemia. 

Observational studies In a single-center study in 86 liver transplant recipients taking sirolimus, eight had too short a follow-up to include them in the analysis of long-term results, 38 were treated with sirolimus as the main immunosuppressant, and the other 40 took sirolimus-I-caldneurin inhibitors [124. Of the 86 patients, 82 developed a total of 92 adverse reactions hyperlipidemia ( =44), leg edema ( =20), anemia ( = 12), oral ulcers (n=5), rashes (n=5), diarrhea and leukopenia (two each), and thrombocytopenia and cardiomyopathy (one each). Sirolimus was withdrawn because of severe adverse reactions in seven cases, including generalized rashes (n=3), and cardiomyopathy, leg edema, diarrhea, anemia, and oral ulcers (one each). Rashes and cardiomyopathy developed soon after sirolimus introduction, the other adverse reactions usually had a gradual onset of several months. The leg edema in 20 patients resolved spontaneously in 7,... 

---